Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Vitamin D and Efavirenz

supplement:

Vitamin D

Research Papers that Mention the Interaction

BackgroundIt was reported that antiretroviral drugs such as efavirenz can increase the catabolism of vitamin D in HIV infected individuals.
BMC Research Notes  •  2012  |  View Paper
Efavirenz use can negatively influence vitamin D levels and supplementation is necessary as a likely adjunct to improving CD4+ T cells, resulting in greater effectiveness of the treatment.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases  •  2021  |  View Paper
HIV and/or antiretroviral therapy (ART), particularly efavirenz (EFV), may interfere with vitamin D metabolism.
The Journal of Steroid Biochemistry and Molecular Biology  •  2017  |  View Paper
Efavirenz induces cytochrome P450 enzymes involved in vitamin D metabolism and may accelerate the catabolism of 25-(OH)D and 1,25-(OH)2D3, the latter being the active vitamin D metabolite (26).
Initiation of efavirenz (EFV), a nonnucleoside reverse transcriptase inhibitor, is associated with a 6.2- to 12.5-nmol/L decrease in 25-hydroxyvitamin D [25-(OH)D] levels (24, 25).
Annals of Internal Medicine  •  2015  |  View Paper
Conclusions Rilpivirine had little effect on 25(OH)D, whereas efavirenz resulted in a significant reduction in 25(OH)D levels and an increase in the risk of severe 25(OH)D deficiency.
Results After 48 weeks, mean 25(OH)D levels remained largely unchanged from baseline with rilpivirine (-0.2 ng/ml; P=0.57 versus no change), but were significantly reduced with efavirenz (-2.5 ng/ml; P<0.0001 versus no change).
Antiviral therapy  •  2014  |  View Paper
Patients receiving efavirenz had a trend toward lower serum 25(OH)D concentrations (11.1 ± 4.6 ng/mL vs. 14.6 ± 7 ng/mL, P = 0.1).
The Pediatric infectious disease journal  •  2013  |  View Paper
Efavirenz is associated with a reduction in 25-hydroxy vitamin D levels, tenofovir with secondary hyperparathyroidism, and cART with increased bone turnover and low BMD.
AIDS  •  2012  |  View Paper
Low vitamin D status is common and needs to be assessed among HIV-infected patients including tropical residents especially when EFV is used.
Multivariate analysis showed that receiving efavirenz (EFV) was significantly associated with low vitamin D status (odds ratio = 3.60; 95% confidence interval, 1.06-12.15, P <.05).
Journal of the International Association of Physicians in AIDS Care  •  2012  |  View Paper
Conclusions ART initiation with EFV is associated with significant decreases in 25(OH)D and an increased risk of hypovitaminosis D compared with non-EFV regimens.
Antiviral therapy  •  2010  |  View Paper
Some studies have also shown that efavirenz may cause unfavorable changes in lipid parameters and reductions in vitamin D levels.
Research initiative, treatment action : RITA  •  2000  |  View Paper